Home Newsfeeds Barclays Maintains Equal-Weight on Biogen, Raises Price Target to $275

Barclays Maintains Equal-Weight on Biogen, Raises Price Target to $275

Barclays analyst Carter Gould maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $200 to $275.

byBenzinga Newsdesk

October 7, 2022

1 minute read

Barclays analyst Carter Gould maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $200 to $275.

$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today

By Benzinga Insights

January 25, 3:30 PM

Danaher (NYSE:DHR) has outperformed the market over the past 5 years by 13.99% on an annualized basis producing…

DHR

Needham Maintains Buy on N-able, Raises Price Target to $12

By Benzinga Newsdesk

September 12, 6:06 AM

Needham analyst Mike Cikos maintains N-able (NYSE:NABL) with a Buy and raises the price target from $11 to $12.

NABL

HeartBeam Granted Patent For Signal Transformation From Vector Electrocardiogram To 12-Lead Electrocardiogram

By Benzinga Newsdesk

September 28, 8:33 AM

Patented Technology Allows HeartBeam AIMIGo™ Credit Card-sized Device to Enable a 12-lead ECG Anytime, Anywhere HeartBeam, Inc. (NASDAQ:BEAT), a cardiac technology company that has developed the first

BEAT

Nasdaq Surges 100 Points; Walmart Raises Full-Year Outlook

By Lisa Levin

May 18, 12:09 PM

U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded up 0.09% to 33,451.95 while the NASDAQ rose 0.79% to 12,599.66. The S&P 500, also rose, gaining, 0.44% to 4,177.22.

ELTK

Barclays Maintains Equal-Weight on Biogen, Raises Price Target to $275

Related Posts

$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today

Needham Maintains Buy on N-able, Raises Price Target to $12

HeartBeam Granted Patent For Signal Transformation From Vector Electrocardiogram To 12-Lead Electrocardiogram

Nasdaq Surges 100 Points; Walmart Raises Full-Year Outlook